Skip to content
Artwork for RhAPPcast
Health & FitnessMedicineEducationScience

RhAPPcast

Rheumatology Advanced Practice Providers (RhAPP)

This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).

Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases.

Play
  • 37 episodes
  • a few times a week
  • Avg 11 min
  • English
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • Thursday · 3 min

    FAQ: What Is The Role of FcRn in Sjogren's Pathogenesis?

    In this FAQ video module, Robert Laugherty, explains the role of the neonatal Fc receptor (FcRn) in autoimmune disease, with a focus on Sjögren’s disease. He reviews how FcRn protects immunoglobulin G (IgG) antibodies from degradation and recycles them into circulation, extending their half-life. The discussion explores how this normal immune function can also prolong the presence of pathogenic autoantibodies that contribute to autoimmune inflammation. This episode examines the rationale for FcRn inhibition and the mechanism of action of nipocalimab, a therapy being investigated for Sjögren’s disease and systemic lupus erythematosus (SLE). Robert explains how blocking FcRn interrupts IgG recycling and lowers circulating IgG levels, including disease-associated autoantibodies. He discusses why researchers are studying this approach to address autoimmune disease activity, including the glandular and systemic manifestations of Sjögren’s disease, while highlighting ongoing clinical research. Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, and other healthcare professionals, this educational overview connects antibody biology with emerging therapeutic approaches in rheumatology. Learn how FcRn-mediated IgG recycling contributes to the rationale for investigating targeted treatments in autoantibody-associated diseases. For more rheumatology education and clinical resources, explore the RhAPP Content Rheum and RhAPP ACE app.

  • November 14 · 7 min

    Podcast: Recap of Obesity Treatment in Rheumatology

    In this educational discussion, Christine Stamatos and Angela McNair explore the connection between obesity, chronic inflammation, and rheumatic disease following their presentation at the 2026 RhAPP meeting. They discuss the role of adipose tissue in inflammatory cytokine activity and examine how obesity may affect disease burden and treatment response in patients with inflammatory rheumatic conditions. This episode highlights emerging research on GLP-1-based therapies and psoriatic arthritis (PsA), including the TOGETHER-PsA study, and considers how addressing obesity may complement rheumatologic treatment. Christine and Angela emphasize that comprehensive obesity care extends beyond prescribing medication to include nutrition, physical activity, sleep, stress management, and social support. They also discuss collaboration between rheumatology and obesity medicine providers, the importance of frequent follow-up, and educational opportunities for clinicians incorporating weight management into their practice. Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, and other healthcare professionals, this conversation offers practical perspectives on integrating obesity care into a busy clinical setting. The discussion addresses limited access to specialists, medication access barriers, treatment discontinuation, weight regain, and considerations for preserving muscle and bone health. Throughout the episode, Christine and Angela emphasize individualized care and ongoing patient support to help sustain the benefits of treatment. For more rheumatology education and clinical resources, visit RhAPP’s website, the RhAPP content rheum, or the RhAPP ACE app.

  • November 12 · 7 min

    Medication Review: What Is Icotrokinra's Mechanism of Action and How Is It Administered?

    In this medication review, Robert Casquejo discusses icotrokinra, an oral macrocyclic peptide that selectively targets the interleukin-23 (IL-23) receptor. He explains how IL-23 receptor inhibition affects the IL-23/Th17/IL-17 inflammatory pathway and explores the features that distinguish this oral treatment approach from injectable monoclonal antibodies used in psoriatic disease. This episode reviews psoriasis clinical trial findings, including Investigator’s Global Assessment (IGA) scores of clear or almost clear, 90% improvement in the Psoriasis Area and Severity Index (PASI 90), and longer-term treatment responses through 52 weeks. Robert also discusses reported safety findings, including upper respiratory tract infections and nasopharyngitis, along with practical considerations related to oral administration and medication absorption. The conversation considers how an oral treatment option may support discussions with patients who prefer to avoid injections. Designed for dermatology and rheumatology advanced practice providers, nurse practitioners, physician associates, pharmacists, and other healthcare professionals, this overview examines icotrokinra’s mechanism of action, psoriasis efficacy data, and safety profile. Robert also highlights ongoing clinical trials in psoriatic arthritis (PsA), distinguishing the psoriasis findings discussed from the research evaluating potential applications in joint disease. For more rheumatology education and clinical resources, visit RhAPP’s website, the RhAPP content rheum, or the RhAPP ACE app.

  • November 10 · 1 min

    Medication Review: What Real-World Evidence Supports the Effectiveness of Belimumab in SLE?

    In this Medication Review video, Jennifer Mylod, DNP, discusses recent real-world evidence supporting the effectiveness and safety of belimumab in systemic lupus erythematosus (SLE). As one of the most established biologic therapies for lupus, belimumab continues to demonstrate meaningful benefits for patients across a range of clinical settings. This educational discussion reviews real-world data showing improvements in disease activity, flare reduction, serologic markers, and corticosteroid use among patients treated with belimumab. Jennifer also highlights findings from lupus nephritis studies, which have demonstrated improvements in proteinuria and renal response rates when belimumab is added to standard therapy. Watch now to learn more about the long-term safety and effectiveness of belimumab, including commonly reported adverse events and the reassuring safety profile observed since its approval more than 15 years ago. For more expert-led education, visit the Content Rheum and download the RhAPP Ace app to stay up to date with the latest clinical insights in rheumatologic care.

  • November 5 · 20 min

    RhAPPcast: A Case-Based Approach to Early Intervention and Renal Preservation in Lupus Nephritis

    Stay up to date with the latest guidance in lupus nephritis management in this RhAPPcast episode featuring host Amanda Mixon, PA-C, and Tiffany Terrell, FNP-C. Through a practical case-based discussion, they explore how the latest American College of Rheumatology (ACR) guidelines can be applied in real-world clinical practice to support early detection, timely intervention, and long-term kidney preservation in patients with lupus nephritis. Learn about current recommendations for screening and monitoring patients with systemic lupus erythematosus (SLE), the role of kidney biopsy in diagnosis, and evolving treatment strategies for lupus nephritis. The discussion highlights guideline-directed approaches to therapy selection, treatment monitoring, response assessment, and management of refractory disease, while emphasizing the importance of preserving renal function and improving long-term outcomes. Whether you're a rheumatology provider, advanced practice provider (APP), or healthcare professional caring for patients with lupus, this episode provides practical insights into translating clinical guidelines into everyday practice and optimizing care for patients with lupus nephritis. For more expert-led education, visit the Content Rheum and download the RhAPP Ace app to stay up to date with the latest clinical insights in rheumatologic care.

  • October 31 · 9 min

    RhAPPcast: Introducing the RhAPP Advocacy Program

    In this special edition of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers (RhAPP), Heather Finlayson and Kevin Daley discuss rheumatology advocacy and the importance of strengthening the APP voice in healthcare policy. They introduce the RhAPP Advocacy Committee and explore how nurse practitioners, physician assistants, and pharmacists can get involved in addressing insurance barriers, supporting medication access, and advocating for their patients and practices. This episode highlights key advocacy issues in rheumatology, including step therapy, non-medical switching, prior authorization, prescription drug affordability boards (PDABs), and the federal 340B Drug Pricing Program. Heather and Kevin discuss how insurance requirements and policy decisions intersect with everyday patient care, sharing practical ways clinicians can participate through legislative outreach, letter writing, virtual testimony, and patient education. The conversation also explores payer advocacy and the importance of bringing clinical experiences and patient perspectives into state and federal policy discussions. Designed for rheumatology APPs and other healthcare professionals, this discussion outlines the committee’s plans for regional leadership, virtual meetings, and ongoing advocacy education. Whether you are new to healthcare advocacy or looking for ways to become more involved, this episode offers an approachable starting point for making your voice heard and helping patients do the same. For more rheumatology education and podcasts, visit RhAPP’s website and explore the RhAPP ACE app.

  • October 29 · 1 min

    FAQ: How Does Combination Therapy of Guselkumab and Golimumab Work in PsA?

    In this FAQ video module, William Saalfeld, NP, explains the rationale for investigational combination therapy with guselkumab and golimumab in psoriatic arthritis (PsA). He reviews how guselkumab targets interleukin-23 (IL-23) and golimumab inhibits tumor necrosis factor (TNF), highlighting how these medications address complementary inflammatory pathways involved in immune activation, synovitis, and joint inflammation. This episode examines the phase 2a AFFINITY study, which compared guselkumab plus golimumab with guselkumab monotherapy. William discusses the primary endpoint of minimal disease activity (MDA), American College of Rheumatology (ACR) response measures, and exploratory findings in patients with elevated C-reactive protein (CRP). He explains that the primary endpoint was not met, while secondary and exploratory analyses suggested potential additional benefits in peripheral joint disease and physical function. The discussion also considers why improvements in psoriasis, enthesitis, and dactylitis did not show a clear additional benefit with combination therapy. Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, and other healthcare professionals, this FAQ offers a concise overview of dual IL-23 and TNF inhibition in psoriatic arthritis. William emphasizes that guselkumab plus golimumab remains investigational, with further research needed to clarify which patients may benefit and its potential role in future PsA treatment strategies. For more expert-led education, visit the Content Rheum and download the RhAPP Ace app to stay up to date with the latest clinical insights in rheumatologic care.

  • October 27 · 7 min

    FAQ: How Does Guselkumab Affect Pregnancy Outcomes?

    In this FAQ video module, Candace Ryan, PA-C, reviews guselkumab and pregnancy outcomes in patients with psoriatic arthritis, psoriasis, and inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. She discusses how the timing of exposure to this IL-23 inhibitor and changes in placental antibody transfer inform conversations about biologic therapy during pregnancy. This episode examines pregnancy safety findings from the Janssen Global Safety Database and a World Health Organization (WHO) pharmacovigilance analysis. Candace reviews reported miscarriages, congenital abnormalities, live births, and comparisons with TNF inhibitors, while explaining the limitations of observational data and spontaneous reporting. She emphasizes why reassuring findings do not establish guselkumab as definitively safe during pregnancy or demonstrate greater safety than TNF inhibitors, particularly given limited data on exposure later in pregnancy. The discussion also explores ACR and EULAR guidance on biologic use during pregnancy and the importance of balancing potential medication risks with the consequences of uncontrolled maternal inflammatory disease. Topics include disease severity, timing of exposure, alternative therapies compatible with pregnancy, and shared decision-making to individualize treatment. Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, and other healthcare professionals, this FAQ offers practical context for reproductive health counseling and treatment decisions involving guselkumab during pregnancy. For more rheumatology education and clinical resources, visit RhAPP’s website, the RhAPP content rheum, or the RhAPP ACE app.

  • October 22 · 3 min

    Journal Club: Guselkumab + Golimumab in Active PsA: Week 24 Phase 2a Results

    In this Journal Club, Claudia Rivera-Salas, DNP, discusses the phase 2a AFFINITY trial evaluating combination therapy for active psoriatic arthritis (PsA). She reviews a randomized, double-blind study comparing guselkumab, an interleukin-23 (IL-23) inhibitor, plus golimumab, a tumor necrosis factor (TNF) inhibitor, with guselkumab alone in adults who had an inadequate response to prior TNF inhibitor treatment. This episode explores the week 24 results, including the study’s primary endpoint of minimal disease activity (MDA), which was not met. Claudia discusses exploratory secondary findings involving ACR20 and ACR50 responses and patient-reported physical health outcomes, along with subgroup findings in participants with elevated baseline C-reactive protein (CRP). She also reviews safety observations through week 36 and considers the questions these early results raise about targeting two inflammatory pathways simultaneously in patients with persistent psoriatic arthritis disease activity. Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, and other healthcare professionals caring for patients with psoriatic arthritis, this discussion offers insight into emerging research on dual IL-23 and TNF inhibition. The review highlights the rationale for combination biologic therapy and the need for further research to clarify its efficacy, safety, and potential role in patients with an inadequate response to TNF inhibitors. Visit the RhAPP Content Rheum or RhAPP ACE app for more rheumatology education, medication reviews, and journal clubs.

  • October 20 · 5 min

    Medication Review: Belimumab Dosing Strategies and Administration in SLE and Lupus Nephritis

    In this medication review, Jessica Tapia, NP, a family nurse practitioner in rheumatology at HonorHealth in Phoenix, Arizona, reviews belimumab (Benlysta) dosing for systemic lupus erythematosus (SLE) and lupus nephritis in adult and pediatric patients. This overview explores intravenous (IV) and subcutaneous administration, highlighting how dosing schedules vary by disease state, age, and body weight. This episode covers initial and maintenance dosing, weight-based pediatric regimens, and considerations for transitioning from IV infusions to subcutaneous injections. Jessica also discusses autoinjector and prefilled syringe options, age-related considerations for each formulation, and key differences between SLE and lupus nephritis dosing. Drawing on her clinical experience, she explains how patient preferences and comfort with self-injection can help guide the choice of administration method. Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, and other clinicians managing lupus and lupus nephritis, this medication review offers practical insights into Benlysta dosing, administration, and individualized treatment planning. For more rheumatology education and clinical resources, visit RhAPP’s website, the RhAPP Content Rheum, or the RhAPP ACE app.

  • October 15 · 4 min

    FAQ: What is the difference between BASDAI and ASDAS?

    In this FAQ video module, Amanda Mixon, PA-C, explains the difference between the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS), two validated tools used to assess disease activity in axial spondyloarthritis. She reviews how BASDAI uses six patient-reported questions to evaluate fatigue, spinal pain, peripheral joint symptoms, enthesitis-related tenderness, and morning stiffness, providing a quick and practical measure of a patient’s overall symptom burden. This episode also explores how ASDAS combines patient-reported symptoms with an objective marker of inflammation, such as C-reactive protein or erythrocyte sedimentation rate. Amanda discusses the established ASDAS disease activity categories, its ability to measure clinically important improvement, and its value in monitoring treatment response, predicting radiographic progression, and supporting clinical decision-making. She also explains why BASDAI scores may remain elevated because of factors beyond active inflammation, including structural damage, osteoarthritis, fibromyalgia, sleep disturbances, or mood disorders. Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, and clinicians caring for patients with axial spondyloarthritis or ankylosing spondylitis, this FAQ highlights why BASDAI and ASDAS should be viewed as complementary tools. BASDAI helps clinicians understand how the patient feels, while ASDAS adds objective evidence of inflammation to provide a more complete picture of disease activity. For more rheumatology education and clinical resources, visit RhAPP’s website, the RhAPP content rheum, or the RhAPP ACE app.

  • October 13 · 4 min

    Medication Review: Guselkumab Label Updates Secondary to Data From the APEX and SOLSTICE Studies

    In this medication review, Amanda Mixon, PA-C, reviews the APEX and SOLSTICE clinical trials and their implications for guselkumab (Tremfya) in active psoriatic arthritis (PsA). This overview highlights the role of IL-23 inhibition in psoriatic arthritis management, including the APEX findings that supported a U.S. prescribing information update addressing inhibition of structural joint damage. This episode explores the APEX data on radiographic progression and the SOLSTICE findings in patients with an inadequate response or intolerance to prior tumor necrosis factor (TNF) inhibitor therapy. Amanda discusses key outcomes across joint symptoms, physical function, enthesitis, dactylitis, skin psoriasis, and minimal disease activity, along with the reported safety findings. The discussion emphasizes how these studies may inform treatment sequencing and conversations about symptom control, joint preservation, and individualized treatment goals. Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, and other clinicians managing psoriatic arthritis, this module offers practical insights into guselkumab clinical trial data, structural damage prevention, and shared decision-making when selecting biologic therapy. For more rheumatology education and clinical resources, visit RhAPP’s website, the RhAPP Content Rheum, or the RhAPP ACE 2.0 app.

  • October 9 · 29 min

    RhAPPcast: The Steroid Tightrope: Managing GC Toxicity in PMR

    Amanda Mixon, PA-C and fellow rheumatology providers Heather Finlayson, PA-C, and Amanda Sell, PA-C, discuss managing glucocorticoid toxicity in polymyalgia rheumatica (PMR), focusing on balancing disease control with long-term patient safety. They explore the challenges of prednisone tapering, recurrent flares, and cumulative steroid exposure, including concerns associated with prolonged use at lower doses. The conversation highlights patient characteristics and comorbidities that may increase toxicity risk, including older age, diabetes, hypertension, osteoporosis, glaucoma, and psychiatric conditions. They review practical monitoring strategies for blood pressure, blood glucose, bone health, infection risk, and changes in weight, sleep, mood, and skin. The discussion also examines treat-to-target approaches and when difficulty tapering, repeated relapses, or steroid-related complications should prompt consideration of steroid-sparing therapy. Throughout the episode, they emphasize patient education, shared decision-making, and coordination across healthcare providers to establish treatment expectations and address patients’ concerns about reducing steroids. Designed for nurse practitioners, physician assistants, and other healthcare professionals caring for patients with PMR, this podcast offers practical insights into glucocorticoid safety, individualized treatment decisions, and reducing steroid burden while maintaining symptom control and quality of life. For more expert-led education, visit the Content Rheum and download the RhAPP Ace app to stay up to date with the latest clinical insights in rheumatologic care.

  • October 8 · 1 min

    FAQ: What is the MOA of guselkumab and icotrokinra?

    In this FAQ video module, Jennifer Mylod, a rheumatology nurse practitioner in Phoenix, Arizona, compares the mechanisms of action of guselkumab and icotrokinra within the interleukin-23 (IL-23)/T-helper 17 (Th17) signaling pathway. This overview highlights the differences between an injectable monoclonal antibody that targets the IL-23 cytokine and an oral peptide that selectively binds the IL-23 receptor. This episode explores guselkumab’s binding to the IL-23 p19 subunit and its interaction with CD64 on IL-23-producing immune cells, alongside icotrokinra’s receptor-targeted approach to blocking IL-23 signaling. Jennifer also discusses downstream inflammatory cytokines, including IL-17A, IL-17F, and IL-22, and their connection to the inflammatory processes involved in psoriasis and psoriatic arthritis. The discussion helps clarify how these different molecular targets intersect within the same inflammatory pathway. Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, and other clinicians caring for patients with psoriasis and psoriatic arthritis, this module offers an overview of IL-23 signaling, targeted therapies, and the distinction between cytokine inhibition and receptor blockade. For more rheumatology education and clinical resources, visit RhAPP’s website, the RhAPP Content Rheum, or the RhAPP ACE app.

  • October 6 · 2 min

    FAQ: How Should Treatment Duration be Approached After Remission or Low Disease Activity in SLE?

    In this FAQ video, Heather Finlayson, PA-C, discusses how treatment duration should be approached after achieving remission or low disease activity in systemic lupus erythematosus (SLE). As treatment options continue to expand and more patients achieve sustained disease control, questions about when and how to taper therapy have become increasingly important. This educational discussion reviews current guideline recommendations for long-term lupus management, including the ongoing role of hydroxychloroquine, strategies for minimizing corticosteroid exposure, and considerations for tapering immunosuppressive therapies after sustained remission. Heather also explores the challenges of determining when treatment reduction may be appropriate, as biologic therapies become more widely used in lupus care. Watch now to learn more about maintaining remission, reducing treatment burden, and the evolving approach to long-term disease management in SLE. For more expert-led education, visit the Content Rheum and download the RhAPP Ace app to stay up to date with the latest clinical insights in rheumatologic care.

  • September 29 · 2 min

    RhAPPcast: SLEDAI Training: Disease Activity in Lupus and Organ Damage Recognition

    In this episode of RhAPPcast, host Amanda Mixon, PA-C, is joined by Jeannette Hart, PA-C, to discuss lupus disease activity assessment and the distinction between active disease and irreversible organ damage. The conversation explores how the SLEDAI-2K can help clinicians organize comprehensive assessments, monitor disease activity across multiple organ systems, and guide treatment decisions for patients with systemic lupus erythematosus (SLE). This episode highlights practical strategies for incorporating disease activity scoring into busy clinic visits, monitoring for lupus nephritis, and recognizing changes that may warrant treatment escalation. Amanda and Jeannette also discuss the limitations of disease activity scores, the importance of clinical judgment when evaluating partial improvements, and balancing inflammation control with reducing long-term glucocorticoid exposure. Through clinical examples, they emphasize individualized patient education, shared decision-making, and collaboration between rheumatology, nephrology, and other specialists to support coordinated lupus care. Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, and other clinicians managing lupus, this discussion offers practical insights into disease monitoring, organ damage prevention, and patient communication. For more rheumatology education and clinical resources, visit RhAPP’s website, the RhAPP Content Rheum, or the RhAPP ACE 2.0 app.

  • September 25 · 2 min

    Medication Review: SLE & Lupus Nephritis: Biologic MOAs Explained

    In this educational Medication Review, Jennifer Mylod, DNP, provides an overview of the biologic and targeted therapies currently available for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN). This video reviews the different mechanisms of action used to target key immune pathways involved in lupus and highlights how these therapies help manage disease activity and improve patient outcomes. Learn how currently available treatments work by targeting B cells, B-cell activating factor (BAFF/BLyS), type I interferon signaling, and other immune pathways that contribute to inflammation and autoantibody production. Jennifer discusses important therapies used in the management of SLE and lupus nephritis, including belimumab, anifrolumab, rituximab, obinutuzumab, and voclosporin, and explains how their mechanisms differ. The discussion also explores the evolving treatment landscape for lupus, emphasizing the growing number of therapeutic options available to help reduce disease activity, preserve organ function, and support long-term disease control. Understanding these mechanisms can help clinicians make informed treatment decisions and optimize care for patients with SLE and lupus nephritis. Watch this video to gain a better understanding of the biologic and targeted therapies used in lupus care and the science behind their clinical use. For more expert-led education, visit the Content Rheum and download the RhAPP Ace app to stay up to date with the latest clinical insights in rheumatologic care.

  • September 24 · 2 min

    FAQ: Why is Earlier Intervention Important in Lupus?

    In this FAQ video, Amanda Mixon, PA-C, discusses why early intervention is critical in the management of systemic lupus erythematosus (SLE). Early diagnosis and treatment are essential for controlling inflammation, preventing irreversible organ damage, and improving long-term patient outcomes. This educational discussion reviews the impact of uncontrolled lupus on major organ systems, including the kidneys, heart, lungs, and brain, and highlights how timely treatment can help reduce disease activity, limit flares, and prevent cumulative damage over time. Amanda also explores the importance of early detection and treatment of lupus nephritis, as well as the potential complications associated with uncontrolled disease, including cardiovascular disease, stroke, osteoporosis, infection, and reduced quality of life. Watch now to learn how early intervention and proactive disease management can help preserve organ function and support better long-term outcomes for patients living with lupus. For more expert-led education, visit the Content Rheum and download the RhAPP Ace app to stay up to date with the latest clinical insights in rheumatologic care.

  • September 23 · 9 min

    Journal Club: Deep Dive Into Radiographic Progression/Data in PsA From The PsA-1 Manuscript

    In this RhAPP Journal Club, Danielle Gatti-Palumbo, a clinical pharmacist in rheumatology, reviews the efficacy and safety of deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, in patients with active psoriatic arthritis (PsA). The presentation focuses on 52-week findings from the phase 3 POETYK PsA-1 trial in patients who had not previously received biologic therapy. Danielle explains TYK2 signaling, patient eligibility, baseline disease characteristics, and the randomized, double-blind, placebo-controlled study design, including the transition from placebo to active treatment after week 16. She examines the primary ACR20 endpoint and additional outcomes, including ACR50 and ACR70 responses, psoriasis improvement measured by PASI 75, minimal disease activity, physical function, fatigue, and quality of life. The discussion also explores enthesitis, dactylitis, and post hoc analyses of radiographic progression, highlighting the importance of distinguishing statistically significant findings from numerical improvements and exploratory results. Additional topics include axial symptoms, treatment response through week 52, and safety findings discussed in the presentation, including acne-like reactions, infections, herpes zoster, laboratory abnormalities, and cardiovascular and thromboembolic safety considerations. Danielle evaluates the study’s strengths and limitations, including the biologic-naive population, absence of an active comparator, interpretation of structural damage findings, and the need for longer-term data. Throughout the journal club, she considers how these results may inform discussions about oral treatment options for patients with active and erosive psoriatic arthritis. Viewers will gain practical insights into interpreting clinical trial endpoints, evaluating efficacy across disease domains, and critically assessing the evidence for TYK2 inhibition in rheumatology practice. Visit the RhAPP Content Rheum or RhAPP ACE app for more rheumatology education, medication reviews, and journal clubs.

  • September 22 · 2 min

    FAQ: How Does Early Intervention and Steroid Reduction Impact Long Term Organ Damage in Lupus

    In this FAQ video module, Tiffany Terrell, NP, reviews the role of early intervention and steroid reduction in minimizing long-term organ damage in systemic lupus erythematosus (SLE) and lupus nephritis. This overview highlights the importance of timely treatment, routine kidney monitoring, and controlling inflammation while limiting prolonged corticosteroid exposure. This episode explores American College of Rheumatology (ACR) recommendations for lupus management, including monitoring for kidney involvement and tapering glucocorticoids as disease activity comes under control. Tiffany also discusses the risks associated with long-term, high-dose steroid use, including infections, osteoporosis, glaucoma, and avascular necrosis. The discussion emphasizes the balance between maintaining disease control and reducing treatment-related complications to support long-term outcomes for patients with lupus. Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, and other clinicians managing lupus and lupus nephritis, this module highlights the importance of proactive monitoring, early treatment, and individualized steroid reduction. For more rheumatology education and clinical resources, visit RhAPP’s website, the RhAPP Content Rheum, or the RhAPP ACE app.

Showing 1–20 of 37 episodes